Director/PDMR Shareholding
26 May 2020 10:30 BST
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that on 21 May 2020, Pascal Soriot, Chief Executive Officer, was granted an award of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.
| PDMR | Ordinary Shares granted under the AZPSP | Award price per Ordinary Share |
| Pascal Soriot | 8,734 | £73.76 |
This award forms part of the AZPSP award granted to Mr Soriot on 6 March 2020 and has been made to take account of the revised limits for the AZPSP approved by shareholders at the Company's 2020 Annual General Meeting. As such, it is subject to a combination of performance measures focused on scientific, commercial and financial performance assessed over a three-year performance period (1 January 2020 to 31 December 2022). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.
Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2019, which is available on the Company's website at www.astrazeneca.com/annualreport2019.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Pascal Soriot | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Chief Executive Officer | ||||
| b) | Initial notification /Amendment | Initial notification | ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | AstraZeneca PLC | ||||
| b) | LEI | PY6ZZQWO2IZFZC3IOL08 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 |
||||
| b) | Nature of the transaction | Grant of a share award under the AstraZeneca Performance Share Plan | ||||
| c) | Price(s) and volume(s) |
|
||||
| d) | Aggregated information - Aggregated volume - Price |
Not applicable - single transaction | ||||
| e) | Date of the transaction | 21 May 2020 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.